

Brendan M Everett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5425845/publications.pdf>

Version: 2024-02-01

72
papers

15,986
citations

94381

37
h-index

88593

70
g-index

73
all docs

73
docs citations

73
times ranked

20236
citing authors

#	ARTICLE	IF	CITATIONS
1	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2022, 24, 169-180.	2.9	23
2	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
3	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2022, 175, W4.	2.0	0
4	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2022, 175, W4-W5.	2.0	0
5	Cardiac Involvement in Athletes Recovering From COVID-19: A Reason for Hope. <i>Circulation</i> , 2021, 144, 267-270.	1.6	6
6	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
7	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
8	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1528-1541.	2.0	52
9	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1703.	3.8	186
10	Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. <i>Rheumatology</i> , 2021, 60, 3789-3798.	0.9	5
11	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in CANTOS. <i>Arthritis Care and Research</i> , 2021, , .	1.5	3
12	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020, 180, 141.	2.6	17
13	Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 495-504.	0.9	16
14	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 1359-1365.	1.0	12
15	Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores. <i>Rheumatology International</i> , 2020, 40, 257-261.	1.5	20
16	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	2.0	126
17	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1117-1145.	1.2	276
18	Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death. <i>Circulation</i> , 2020, 142, 1148-1158.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Targeting Inflammation to Reduce Residual Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2020, 22, 66.	2.0	29
20	Inhibition of Interleukin-1 β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1660-1670.	1.2	110
21	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020, 43, 2684-2690.	4.3	13
22	Comparative Risks of Cardiovascular Disease in Patients With Systemic Lupus Erythematosus, Diabetes Mellitus, and in General Medicaid Recipients. <i>Arthritis Care and Research</i> , 2020, 72, 1431-1439.	1.5	24
23	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. <i>BMJ</i> , The, 2020, 370, m2812.	3.0	7
24	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 840-846.	1.6	18
25	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 389-395.	1.6	22
26	Residual Inflammatory Risk. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2410-2412.	1.2	11
27	Dyslipidemia Profiles in Patients with Peripheral Artery Disease. <i>Current Cardiology Reports</i> , 2019, 21, 42.	1.3	30
28	Novel Antiatherosclerotic Therapies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 538-545.	1.1	103
29	Heart Failure, the Inflammasome, and Interleukin-1 β . <i>Journal of the American College of Cardiology</i> , 2019, 73, 1026-1028.	1.2	6
30	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306.	4.3	157
31	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019, 380, 752-762.	13.9	886
32	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. <i>Circulation</i> , 2019, 139, 1289-1299.	1.6	384
33	Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population. <i>Arthritis Care and Research</i> , 2019, 71, 104-115.	1.5	15
34	Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1392-1398.	2.9	13
35	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 360, k119.	2.4	132
36	Statins in Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 1447-1449.	1.6	11

#	ARTICLE	IF	CITATIONS
37	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2392-2401.	1.2	236
38	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 319-328.	6.3	628
39	CS-19â€¦Heart failure hospitalizations among SLE and diabetes mellitus patients compared to the general U.S. medicaid population. , 2018, , .		0
40	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3200-3223.	1.2	251
41	Hypoglycemia and Elevated Troponin in Patients With Diabetes and CoronaryÂArtery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1778-1786.	1.2	26
42	Rationale and design of the Pema fibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018, 206, 80-93.	1.2	276
43	Relationship of Interleukin-1Î² Blockade With Incident Gout and Serum Uric Acid Levels. <i>Annals of Internal Medicine</i> , 2018, 169, 535.	2.0	74
44	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1432-1433.	1.2	1
45	Inhibition of Interleukin-1Î² by Canakinumab and Cardiovascular Outcomes in Patients With ChronicÂKidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2405-2414.	1.2	186
46	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). <i>European Heart Journal</i> , 2018, 39, 3499-3507.	1.0	375
47	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1823-1831.	2.9	70
48	Effect of interleukin-1Î² inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1833-1842.	6.3	948
49	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
50	Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 41-47.	2.3	8
51	Assessing the Effects of Diet and Behavior on Cardiovascular Disease: The Role of Biomarkers in Understanding Biology and Mechanism. <i>Clinical Chemistry</i> , 2016, 62, 1169-1171.	1.5	1
52	Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. <i>European Heart Journal</i> , 2016, 37, 2428-2437.	1.0	200
53	Finding Efficacy in a Safety Trial. <i>Circulation</i> , 2016, 134, 773-775.	1.6	3
54	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <i>Lancet Diabetes and Endocrinology,the</i> , 2016, 4, 840-849.	5.5	159

#	ARTICLE	IF	CITATIONS
55	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. <i>American Journal of Hypertension</i> , 2016, 29, 1117-1124.	1.0	13
56	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. <i>American Journal of Cardiology</i> , 2016, 117, 376-381.	0.7	10
57	Interaction of Impaired Coronary Flow Reserve and Cardiomyocyte Injury on Adverse Cardiovascular Outcomes in Patients Without Overt Coronary Artery Disease. <i>Circulation</i> , 2015, 131, 528-535.	1.6	135
58	High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention. <i>Circulation</i> , 2015, 131, 1851-1860.	1.6	113
59	Reducing LDL with PCSK9 Inhibitors – The Clinical Benefit of Lipid Drugs. <i>New England Journal of Medicine</i> , 2015, 373, 1588-1591.	13.9	120
60	Response to Letter Regarding Article, “Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Tj ETQq0 0 0 rgBT / Overlock 40 Tf 50 53		
61	Novel Genetic Markers Associate With Atrial Fibrillation Risk in Europeans and Japanese. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1200-1210.	1.2	127
62	B-Type Natriuretic Peptides Improve Cardiovascular Disease Risk Prediction in a Cohort of Women. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1789-1797.	1.2	25
63	Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. <i>American Heart Journal</i> , 2013, 166, 199-207.e15.	1.2	347
64	Effects of Interleukin-1 β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen. <i>Circulation</i> , 2012, 126, 2739-2748.	1.6	481
65	Sensitive Cardiac Troponin T Assay and the Risk of Incident Cardiovascular Disease in Women With and Without Diabetes Mellitus. <i>Circulation</i> , 2011, 123, 2811-2818.	1.6	106
66	Physical Activity and the Risk of Incident Atrial Fibrillation in Women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 321-327.	0.9	105
67	Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein. <i>Circulation</i> , 2010, 121, 143-150.	1.6	157
68	Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. <i>Atherosclerosis</i> , 2009, 202, 282-288.	0.4	39
69	Using inflammatory biomarkers to guide lipid therapy. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 29-34.	0.8	3
70	Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: A prespecified subgroup analysis of a community-based, randomized, open-label trial. <i>Clinical Therapeutics</i> , 2008, 30, 661-672.	1.1	32
71	Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2007, 83, 592-597.	0.7	76
72	The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2235-2242.	1.2	109